Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca53 Novartis Pharmaceuticals44 Eli Lilly and Company33 Merck Sharp & Dohme LLC31 GlaxoSmithKline31
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Texas

1965 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Illinois, Rhode Island, Tennessee, Texas
2026-01-06
Recruiting
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
NCT07343960Moderate Hepatic Impairment
DrugCapivasertib
AstraZeneca
Phase 1
20
California, Texas
2026-01-06
Recruiting
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919Advanced Solid Tumors
DrugsLumakras·Sotorasib·Panitumumab
Amgen
Phase 2
14
Florida, Texas
2026-01-02
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM)
DrugsLinvoseltamab·Darzalex·Velcade·Carfilzomib
Regeneron Pharmaceuticals
Phase 3
915
Georgia, New York, Ohio, Texas
2026-01-02
Not yet open
Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds
NCT07318792Wound Chronic Draining, Wound Closure
Estar Medical dba Medical Technologies, LTD
Phase 2
16
Florida, Texas
2026-01-01
Recruiting
MultiCenter IDE Study of the PEEK-OPTIMA™ Femoral Component vs a CoCr Alloy TKA Femoral Component of Similar Design
NCT06627673Knee Osteoarthritis
Maxx Orthopedics Inc
Not applicable
200
Kansas, Texas
2026-01-01
Recruiting
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598Leukemia, Myelomonocytic, Chronic
DrugsPacritinib·Hydroxyurea
Theradex
Phase 2
66
Florida, Georgia, Minnesota, Texas
2026-01-01
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT07157033Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma
Phase 1/2
36
California, Michigan, New Mexico, Texas
2026-01-01
Recruiting
DPTX3186 in Wnt Pathway Activated Solid Tumors
NCT07312903Solid Tumors
Dewpoint Therapeutics
Phase 1
40
Texas, Virginia
2026-01
Recruiting
Enhancing Heart Allograft Function With the OCS Heart System Trial
NCT07145515Heart Transplant
TransMedics
Not applicable
655
California, Florida, Massachusetts, New York, North Carolina, Texas
2026-01
Recruiting
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT07392255Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Phase 1/2
75
Indiana, Nevada, Texas, Wisconsin
2025-12-30
Active, closed
Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems
NCT07296263Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Hyperfine
Not applicable
85
Florida, Massachusetts, New York, Pennsylvania, Texas
2025-12-30
Recruiting
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
NCT07223229Non-segmental Vitiligo
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2
45
California, Florida, Massachusetts, Ohio, Texas
2025-12-30
Recruiting
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
NCT07399678Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
DrugALV-100
Alveus Therapeutics, Inc.
Phase 1
180
Florida, Ohio, Texas
2025-12-29
Active, closed
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
NCT07226622Wilson Disease
Prime Medicine, Inc.
Observational
30
California, Connecticut, Illinois, Massachusetts, Michigan, Texas
2025-12-29
Recruiting
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
NCT07815678Obesity
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Georgia, Tennessee, Texas
2025-12-29
Recruiting
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320Bipolar I Disorder, Mania
DrugNBI-1117568
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Recruiting
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07318805Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
DrugsEnlituo·Zirabev·Erbitux·Avastin
Pfizer
Phase 1
260
California, Michigan, New York, Texas, Utah
2025-12-23
Recruiting
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156Gout
DrugMethotrexate
Protalix
Phase 2
150
Arizona, Arkansas, California, Florida, Georgia, Michigan, Pennsylvania, Texas
2025-12-22
Recruiting
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
NCT06975787Lupus Nephritis (LN)
DrugsVonsetamig·Odronextamab
Regeneron Pharmaceuticals
Phase 1
90
California, Minnesota, Texas
2025-12-22
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686Obesity, Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-12-19
Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT07305818Graves Disease
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants
NCT07225517Healthy Volunteer
Biogen
Phase 1
104
Texas
2025-12-18
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
DrugsNXP900·Osimertinib
Nuvectis Pharma, Inc.
Phase 1
18
Maryland, Massachusetts, Oregon, Pennsylvania, Texas, Virginia
2025-12-18
Recruiting
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
85
California, Nevada, New Jersey, Texas
2025-12-18
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
NCT07266428Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
NCT07246590Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
Florida, Indiana, Maryland, Tennessee, Texas
2025-12-17
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Indiana, New York, Ohio, Oregon, Texas
2025-12-17
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Active, closed
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
NCT07215468HIV -1 Infection
DrugVRC07-523LS
TaiMed Biologics Inc.
Phase 2
88
California, Florida, Nevada, New York, Texas
2025-12-16
Recruiting
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
NCT07247110Malignant Neoplasm
DrugsCetuximab·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
250
New Jersey, Texas, Virginia
2025-12-16
Recruiting
ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health
NCT07505797Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms
iSono Health, Inc.
Observational
800
California, Texas
2025-12-16
Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New Jersey, New York, Texas
2025-12-16
Not yet open
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
NCT06731075Type 2 Diabetes Mellitus
Oramed, Ltd.
Phase 3
300
Texas
2025-12-15
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
NCT07052929X-Linked Myotubular Myopathy
DrugsSirolimus·Methylprednisolone·Prednisolone
Astellas Gene Therapies
Phase 1/2
9
Illinois, Massachusetts, Oregon, Texas
2025-12-15
Recruiting
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
NCT07293754Advanced Malignant Solid Tumor
Repertoire Immune Medicines
Phase 1/2
150
Michigan, New York, Texas
2025-12-12
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
DrugsBGB-43395·Fulvestrant
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
NCT07089836Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum
American Laboratory Products Company
Observational
1,000
California, Florida, Texas
2025-12-10
Recruiting
BTM-3566 in Advanced Solid Tumors
NCT07266285Advanced Solid Tumors
DrugBTM-3566
Bantam Pharmaceuticals
Phase 1
30
Texas
2025-12-10
Recruiting
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
HealthTech Wound Care
Phase 4
150
Florida, Michigan, North Carolina, Ohio, Texas, Virginia
2025-12-10
Recruiting
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
NCT06910943Choline Deficiency, Liver Injury
Protara Therapeutics
Phase 2/3
129
Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas
2025-12-10
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
DrugsPF-08634404·Atezolizumab
Pfizer
Phase 2/3
550
Arkansas, Florida, Ohio, Texas, Virginia
2025-12-09
Recruiting
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
NCT06602271Postoperative Pain, Acute
DrugPF614
Ensysce Biosciences
Phase 3
320
Georgia, Texas, Utah
2025-12-09
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
California, New Jersey, South Carolina, Texas
2025-12-09
Recruiting
Knee Flexionater to Avoid Motion Restoring Surgery
NCT07454356Joint Contractures, Total Knee Anthroplasty, Knee Arthrofibrosis
Ermi LLC
Not applicable
150
Texas
2025-12-09
Recruiting
A Study of NTX-1472 in Social Anxiety Disorder
NCT07323784Social Anxiety Disorder (SAD)
Newleos Therapeutics, Inc.
Phase 2
100
California, Florida, Massachusetts, Nevada, New York, Tennessee, Texas
2025-12-09
Active, closed
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
NCT07700433Back Pain
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Ohio, Texas
2025-12-08
Recruiting
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
NCT07276789Non Small Cell Lung Cancer (NSCLC)
Integro Theranostics
Phase 2
35
Pennsylvania, Texas
2025-12-08
Active, closed
EMVITAL + EMFACE Combination Therapy for Temporomandibular Joint (TMJ) Pain Relief
NCT07661121Temporomandibular Disorder (TMD), Temporomandibular Joint Pain, Facial Pain, Neck Pain
BTL Industries Ltd.
Not applicable
48
Florida, Kentucky, Texas
2025-12-08
Recruiting
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
NCT07287033Peanut Allergies
Mabylon AG
Phase 1
48
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
California, Texas, Utah
2025-12-05
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
NCT07213817Locally Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
114
Connecticut, Michigan, Pennsylvania, Texas, Virginia
2025-12-05
By invitation
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
NCT07443202Ocular Rosacea
Tarsus Pharmaceuticals, Inc.
Phase 2
155
Texas, Virginia
2025-12-05
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
California, Florida, Illinois, Ohio, South Carolina, Texas, Wisconsin
2025-12-04
Active, closed
A Study to Evaluate AI-09 In Participants With Glabellar Lines
NCT07321834Glabellar Lines
Eirion Therapeutics Inc.
Phase 2
68
Florida, Louisiana, Tennessee, Texas
2025-12-03
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341Metastatic Castration-resistant Prostate Cancer
DrugsValemetostat·Darolutamide
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Active, closed
Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients
NCT07116746Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic
Arthrosi Therapeutics
Phase 2
15
Florida, Mississippi, North Carolina, Pennsylvania, Texas, Washington
2025-12-03
Recruiting
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270Neoplasms
DrugsGSK5764227·Enzalutamide·Fluorouracil·Leucovorin
GlaxoSmithKline
Phase 1
83
Florida, New York, Pennsylvania, Tennessee, Texas
2025-12-03
Active, closed
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
NCT07205900Obese, Obesity
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
267
California, Illinois, Iowa, North Carolina, South Carolina, Tennessee, Texas
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
Recruiting
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505Cancer, Cancer (Solid Tumors)
DrugJMT108
Conjupro Biotherapeutics, Inc.
Phase 1
270
North Carolina, Texas, Virginia
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
NCT07395232Atopic Keratoconjunctivitis
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Active, closed
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
58
Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas
2025-12-01
Recruiting
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing
NCT07326553Diabete Mellitus, Foot Ulcer Chronic
BioXTek
Phase 4
30
Arizona, Texas
2025-12-01
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Recruiting
A Phase 2 Study of CRD-4730 in CPVT
NCT06658899Catecholaminergic Polymorphic Ventricular Tachycardia
DrugCRD-4730
Cardurion Pharmaceuticals, Inc.
Phase 2
12
California, North Carolina, Texas, Utah, Wisconsin
2025-12-01
Recruiting
Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes
NCT07222787Radiculopathy Lumbar, Degenerative Lumbar Disc Disease
Providence Medical Technology, Inc.
Not applicable
250
Arizona, California, Illinois, New York, North Carolina, Ohio, Texas, Utah
2025-12-01
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
NCT07278336Ovarian Cancer
DrugsBevacizumab·Carboplatin
AbbVie
Phase 1
285
California, Colorado, Illinois, Nebraska, Texas, Utah, Virginia
2025-11-27
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Arkansas, California, Florida, Texas
2025-11-26
Recruiting
Robotic Minimally Invasive Inguinal Hernia Repair Post-Market Clinical Study With the DEXTER Robotic System
NCT07181876Inguinal Hernia Repair
Distalmotion SA
Observational
140
New York, Texas
2025-11-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab
Bristol-Myers Squibb
Phase 1/2
252
Maryland, Texas, Utah, Virginia
2025-11-25
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650Hepatocellular Carcinoma (HCC)
DrugsYervoy·Opdivo
Shanghai Henlius Biotech
Phase 1
246
California, Florida, Tennessee, Texas, Washington
2025-11-25
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
NCT07161414Advanced Solid Tumors
DrugsRecombinant Human Hyaluronidase·Rilvegostomig
AstraZeneca
Phase 1
40
North Carolina, Texas, Virginia
2025-11-25
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Indiana, Louisiana, Rhode Island, Texas
2025-11-25
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
DrugDarolutamide
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
NCT07241039Advanced Squamous Tumors
DrugBudigalimab
AbbVie
Phase 1
220
California, Illinois, Michigan, North Carolina, Texas
2025-11-20
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Alabama, Florida, Georgia, Idaho, Massachusetts, Texas
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Leucovorin·Opdivo·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
NCT07026877Abdominal Aortic Aneurysms (AAA)
Bolton Medical
Not applicable
20
Colorado, Florida, Massachusetts, Missouri, New York, Texas, Washington
2025-11-18
Active, closed
A Study of TLC590 for Postsurgical Pain Following Bunionectomy
NCT07222748Postoperative Pain
DrugsTLC590·Liposomal bupivacaine
TLC Biopharmaceuticals, Inc.
Phase 3
304
Florida, Texas
2025-11-17
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
NCT07095868Selected Types of Solid Tumor
Everest Medicines (Beijing) Co., Ltd.
Phase 1/2
94
New York, Texas, Virginia
2025-11-17
Recruiting
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
NCT07095465Lewy Body Dementia Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 3
126
California, Florida, Hawaii, Kansas, New York, Ohio, Oklahoma, Texas
2025-11-14
By invitation
Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
NCT07347379Aphakia Cataract
RxSight, Inc.
Observational
108
Texas
2025-11-13
Recruiting
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
83
California, Florida, Illinois, Iowa, Tennessee, Texas
2025-11-12
Recruiting
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565Advanced Soft Tissue Sarcoma
Ratio Therapeutics, Inc.
Phase 1
48
California, Minnesota, New York, Ohio, Texas
2025-11-12
Recruiting
Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers
NCT07396376Diabetic Foot Ulcer, Wagner Grade 1 - 2, Chronic Wound, Open Wound
Eluciderm Inc
Phase 1/2
15
Illinois, New Jersey, Texas
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
DrugAZD1613
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Florida, Maryland, Nevada, Pennsylvania, Texas, Utah
2025-11-10
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Texas, Virginia
2025-11-10
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
NCT07220876Open Angle Glaucoma (OAG)
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, Ohio, Pennsylvania, Texas, Wisconsin
2025-11-07
Active, closed
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT07190807Chronic Pain, Intractable Pain, Low Back Pain, Chronic Low-back Pain
Boston Scientific Corporation
Not applicable
70
Colorado, Florida, Louisiana, New York, Pennsylvania, South Carolina, Texas
2025-11-07
Recruiting
18F-mFBG Imaging for Myocardial Sympathetic Innervation
NCT06965621Heart Failure, Ischemic Cardiomyopathy, ICD Patients
DrugMeta-fluorobenzylguanidine
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2
20
Texas
2025-11-05
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
DrugsTrastuzumab·Cetuximab
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Recruiting
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
NCT07064122Haematologic Neoplasms
AstraZeneca
Phase 1
72
Florida, Texas
2025-11-03
Recruiting
Prospective, In-Vivo, Post-Market Safety and Efficacy Surveillance Registry of the MAXX Orthopedics, Freedom Total Knee® System
NCT06627699Knee Osteoarthristis, Total Knee Anthroplasty
Maxx Orthopedics Inc
Observational
300
Kansas, Texas
2025-11-01
Recruiting
SAINT in Postpartum Depression (PPD)
NCT07210255Postpartum Depression (PPD)
Magnus Medical
Not applicable
192
Massachusetts, New York, South Carolina, Texas
2025-11-01
Recruiting
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
NCT07187297Wrinkle, Lax Skin, Lines Skin
Bausch Health Americas, Inc.
Not applicable
164
California, Illinois, Massachusetts, New York, Texas
2025-10-31
Recruiting
EDX110 Randomized Control Trial for Treatment of DFUs
NCT07209358Wound Heal, Diabetic Foot Ulcer
ConvaTec Inc.
Not applicable
298
Arizona, California, Texas
2025-10-30
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
DrugDato-DXd
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Active, closed
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
NCT06859788Meniere's Disease, Ménière's Disease
DrugEbselen
Sound Pharmaceuticals, Incorporated
Phase 3
200
California, Florida, New York, Pennsylvania, South Carolina, Texas, Wisconsin
2025-10-29
Recruiting
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
NCT07218796Cataract, Glaucoma, Ocular Hypertension
DrugsBimatoprost Implant System·Timolol Maleate Ophthalmic
SpyGlass Pharma, Inc.
Phase 3
400
Texas
2025-10-28
Active, closed
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
NCT07199569Monkeypox (Mpox)
DrugJynneos
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT06992258Colorectal Cancer
DrugsLonsurf·Fruquintinib
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
By invitation
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
NCT06986447Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
HRI-MAIL-NIT
Observational
1,689
Arizona, Ohio, Texas
2025-10-25
Recruiting
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.
Phase 1/2
6
Alabama, California, Massachusetts, Ohio, Oregon, Pennsylvania, Texas
2025-10-24
Recruiting
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
NCT07207369Acne Scars
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
The Short Sleep Study
NCT07567560Short Sleepers
Danisco
Observational
34
Florida, Massachusetts, New York, Texas
2025-10-23
Recruiting
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634Duchenne Muscular Dystrophy
Solid Biosciences Inc.
Phase 3
80
Arkansas, Texas, Virginia
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
California, Kentucky, Michigan, New Jersey, New York, Texas
2025-10-21
Recruiting
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
NCT07197645Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 1
33
Florida, Texas
2025-10-21
Recruiting
Pivotal Study of the Velocity™ pAVF System
NCT07153939Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Venova Medical
Not applicable
126
Alabama, California, Florida, New York, North Carolina, South Carolina, Texas
2025-10-21
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
California, Florida, Illinois, Oregon, Pennsylvania, Tennessee, Texas, Utah
2025-10-20
Active, closed
A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
NCT07214272Skin Resurfacing
Bausch Health Americas, Inc.
Not applicable
49
California, Florida, Illinois, New York, Texas
2025-10-17
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT07160725Solid Tumours
DrugPumitamig
Bristol-Myers Squibb
Phase 1/2
540
California, Pennsylvania, South Dakota, Texas, Utah, Washington
2025-10-15
Recruiting
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
NCT07218783Cataract, Glaucoma, Ocular Hypertension
DrugsBimatoprost Implant System·Timolol Maleate Ophthalmic
SpyGlass Pharma, Inc.
Phase 3
400
Texas
2025-10-15
Active, closed
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635Aphakia, Presbyopia
Alcon Research
Not applicable
110
California, Missouri, South Carolina, Texas, Utah
2025-10-14
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
DrugsDurvalumab·Carboplatin
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
Recruiting
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
NCT07204418Healthy Volunteers
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
56
California, Kansas, Texas
2025-10-13
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Texas
2025-10-13
Recruiting
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
NCT07223125Advanced-stage Solid Tumors
Janssen Research & Development, LLC
Phase 1
360
Florida, Texas
2025-10-10
Recruiting
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
NCT07166601Advanced Solid Tumor
DrugsMFOLFIRINOX·Pembrolizumab
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Connecticut, New York, Texas
2025-10-10
Recruiting
FebriDx® Pediatric Validation Study
NCT07211997Acute Respiratory Infections (ARIs)
Lumos Diagnostics
Observational
800
California, Florida, Ohio, Pennsylvania, South Carolina, Texas
2025-10-09
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Recruiting
A Study of V118E in Healthy Participants (V118E-003)
NCT07168915Healthy
DrugPrevnar 20
Merck Sharp & Dohme LLC
Phase 1
126
Florida, Missouri, Texas
2025-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
DrugKarXT
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Missouri, New York, Texas
2025-10-08
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Active, closed
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
DrugSparsentan
Travere Therapeutics, Inc.
Phase 4
20
Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin
2025-10-07
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06988488Multiple Myeloma
DrugsMezigdomide·Elranatamab·Dexamethasone
Celgene
Phase 1/2
62
Alabama, Connecticut, New Jersey, Texas
2025-10-07
Active, closed
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
NCT07216781Healthy Adults
Minicircle
Phase 1
14
Texas
2025-10-06
By invitation
Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings
NCT07214896Mobility Impairment, Clinical Workflow Optimization, Sanitation Protocol Compliance, ESG-linked Healthcare Robotics Deployment
Truway Health, Inc.
Phase 2
400
New York, Texas
2025-10-06
Recruiting
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
NCT06613568End Stage Kidney Disease
Diality Inc.
Not applicable
50
California, New York, Tennessee, Texas, Washington
2025-10-06
Recruiting
Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai
NCT07220863Breast Cancer Awareness
Feminai
Observational
300
Texas
2025-10-05
Recruiting
VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration
NCT07224256Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Neuralink Corp
Not applicable
6
Texas
2025-10-03
Recruiting
A Study of DS5361b in Participants With Advanced Solid Tumors
NCT07182591Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Daiichi Sankyo
Phase 1
192
Florida, Rhode Island, Texas, Virginia
2025-10-02
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099Sjögren, Sjogren Disease, Sjogren's Syndrome
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
36
Florida, New York, Tennessee, Texas, Utah
2025-10-01
Recruiting
EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures
NCT07020520Ureteral Stricture
Urotronic Inc.
Not applicable
60
California, Florida, Indiana, New York, Texas, Utah
2025-10-01
Not yet open
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
NCT06866236Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
DrugEseronate
Ebima Clifford Okundaye
Phase 2/3
3,000
Texas
2025-10
Recruiting
Caesar Foot Take-Home Validation Testing
NCT07075198Prosthesis User, Lower Limb Amputation Below Knee (Injury)
Liberating Technologies, Inc.
Not applicable
18
Texas
2025-10
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
NCT07022483Endometrial Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
Non-invasive Intracranial Pressure Estimation by Measurement of the Occlusion Pressure of the Isolated Periorbital Vein
NCT07222826Intracranial Pressure, Intracranial Pressure Changes
Compremium AG
Not applicable
15
Texas
2025-09-30
Recruiting
Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)
NCT07016698Peripheral Arterial Disease(PAD)
C. R. Bard
Not applicable
600
Florida, Texas
2025-09-29
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
Arizona, California, Florida, Minnesota, Texas, Utah
2025-09-29
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
DrugsUS-sourced Keytruda·Pembrolizumab
Shanghai Henlius Biotech
Phase 1
174
California, Florida, Texas, Washington
2025-09-26
Active, closed
A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease
NCT07168356Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 1
32
Florida, Texas
2025-09-26
Recruiting
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
NCT06441331Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor
Drug177Lu-edotreotide
ITM Solucin GmbH
Phase 1
20
California, Ohio, Pennsylvania, Texas
2025-09-26
Recruiting
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy
Opus Genetics, Inc
Phase 1/2
10
California, Florida, New York, Ohio, Texas
2025-09-25
Recruiting
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
NCT06776783Respiratory Distress Syndrome, Pre-term Infants
Aerogen Pharma Limited
Phase 3
520
Arkansas, California, Florida, Indiana, New Jersey, New York, Texas, Virginia
2025-09-24
Recruiting
An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera
NCT07148999Infertility (IVF Patients)
Urmila DIwekar
Phase 1/2
200
Texas
2025-09-23
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
310
Michigan, Texas, Utah, Virginia
2025-09-23
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
California, Michigan, Pennsylvania, Texas, Virginia
2025-09-23
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
California, Minnesota, Texas
2025-09-19
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
NCT07207707Solid Tumor Malignancies
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT07190469Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
ProteinQure Inc.
Phase 1
80
Texas, Utah
2025-09-16
Not yet open
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
NCT05062902Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
HillMed Inc.
Phase EARLY_PHASE1
46
Texas
2025-09-15
Recruiting
Phagenyx® Registry Study
NCT06866418Dysphagia
Phagenesis Ltd.
Observational
600
Arizona, New Jersey, Texas
2025-09-15
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
DrugsApitegromab·Nusinersen·Risdiplam
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Recruiting
AMEND TS Early Feasibility Study
NCT06951672Symptomatic Functional MR 3 or Greater
Valcare Medical Ltd.
Not applicable
15
Arizona, California, Georgia, Indiana, New York, Oregon, Tennessee, Texas
2025-09-11
Recruiting
tAN for First Responders
NCT07109349Mental Fatigue, Mental Stress
Spark Biomedical, Inc.
Not applicable
30
Texas
2025-09-10
Active, closed
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics
Phase 2
10
Florida, North Carolina, Ohio, Oregon, Texas
2025-09-10
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
NCT07060716Kidney Transplant Rejection, Cell-free DNA
Insight Molecular Diagnostics
Observational
125
California, Florida, Ohio, Pennsylvania, Tennessee, Texas, Utah
2025-09-08
Recruiting
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
NCT07061288Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Phase 1
131
California, Florida, Georgia, Illinois, New Jersey, Texas
2025-09-03
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Recruiting
Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity
NCT06923995Depression Disorders, Anxiety Disorders
Deliberate Solutions Inc.
Not applicable
120
Texas
2025-09-01
Recruiting
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
DrugValbenazine
Neurocrine Biosciences
Phase 4
100
Arkansas, California, Florida, Georgia, Illinois, Nebraska, Ohio, Texas
2025-08-29
Recruiting
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors
NCT07128303Advanced Solid Tumor
DrugsPemetrexed·Carboplatin·Pembrolizumab
Gilead Sciences
Phase 1
476
Massachusetts, Texas, Virginia
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Florida, Iowa, Louisiana, Michigan, New York, Ohio, South Dakota, Texas
2025-08-28
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Active, closed
A Study Evaluating TRIV-509 in Atopic Dermatitis
NCT07167758Atopic Dermatitis
Triveni Bio
Phase 2
95
California, Florida, Indiana, Pennsylvania, Texas, Washington
2025-08-26
Recruiting
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
NCT06977724Dry Eye Syndrome, Systemic Lupus Erythematosus
DrugABBV-319
AbbVie
Phase 1
36
Florida, Illinois, Tennessee, Texas
2025-08-26
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
DrugBudoprutug
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, Massachusetts, New York, Texas
2025-08-25
Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
NCT07108114Metastatic Solid Tumors
Solve Therapeutics
Phase 1
70
California, Missouri, Ohio, Pennsylvania, Texas, Washington
2025-08-25
Recruiting
Epidemiology and Biomarker Study in Alzheimer's Disease
NCT07142954Alzheimer Disease
Eli Lilly and Company
Phase 3
3,400
Texas
2025-08-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Florida, Tennessee, Texas
2025-08-25
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
DrugIDOV-Immune
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
NCT06830863EGFR Inhibitor-associated Rash
Azitra Inc.
Phase 1/2
32
Arkansas, Connecticut, New York, Ohio, Texas, Virginia
2025-08-25
Recruiting
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925Non Hodgkin's Lymphoma Refractory/Relapsed
DrugsFludara·Cytoxan·Fludarabine·Rituximab
ImmunityBio, Inc.
Phase 1
20
California, Texas
2025-08-22
Recruiting
Study of BHV-1300 in Graves' Disease
NCT06980649Graves Disease
DrugBHV-1300
Biohaven Therapeutics Ltd.
Phase 1
15
California, Florida, Georgia, North Carolina, Ohio, Tennessee, Texas
2025-08-21
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
DrugSPY072
Spyre Therapeutics, Inc.
Phase 2
285
Arizona, California, Florida, Illinois, Maryland, Pennsylvania, Texas
2025-08-21
Recruiting
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
NCT07144111Hepatic Impairment
DrugInavolisib
Genentech, Inc.
Phase 1
32
California, Florida, Texas
2025-08-21
Recruiting
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT06998407HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsAVZO-021·Letrozole·Fulvestrant
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
ALX Oncology Inc.
Phase 1
170
California, Florida, Michigan, New Jersey, Ohio, Oregon, Texas, Utah
2025-08-18
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
California, Colorado, Georgia, Massachusetts, New York, Ohio, Pennsylvania, Texas
2025-08-18
Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103Solid Tumors
Exelixis
Phase 1
150
Arkansas, California, District of Columbia, Florida, Michigan, New Jersey, North Carolina, Texas
2025-08-18
Recruiting
Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
NCT07209475Diabetic Foot Ulcer (DFU), Amnio-Maxx
Royal Biologics
Phase 4
248
California, Florida, Georgia, Nebraska, New York, Oklahoma, Texas
2025-08-14
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179Geographic Atrophy, Age-Related Macular Degeneration
DrugSyfovre
AbbVie
Phase 1/2
66
Indiana, Nevada, Texas
2025-08-13
Recruiting
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
NCT07042100Advanced Solid Tumors
DrugPumitamig
Sun Pharma Advanced Research Company Limited
Phase 1
177
Arizona, California, Connecticut, Illinois, Texas
2025-08-12
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
DrugsOpevesostat·Tamoxifen·Exemestane·Letrozole
Merck Sharp & Dohme LLC
Phase 2
250
Alaska, Florida, Louisiana, Nebraska, New Jersey, New York, Ohio, Texas
2025-08-11
Recruiting
A Long-Term Study of JNT-517 in Participants With Phenylketonuria
NCT06628128Phenylketonuria (PKU)
DrugRepinatrabit
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
240
Florida, Oregon, Pennsylvania, Texas, Utah
2025-08-11
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Dato-DXd
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
By invitation
Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures
NCT06795763Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
Elumn8 Medical
Not applicable
115
Georgia, Minnesota, New York, Texas
2025-08-06
Recruiting
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
NCT07021898Metastatic Solid Tumors
Erasca, Inc.
Phase 1
200
Tennessee, Texas, Washington
2025-08-06
Active, closed
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07092865Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 2
168
Kentucky, Missouri, Nebraska, New York, Pennsylvania, Texas
2025-08-06
Recruiting
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT07060989Advanced Solid Tumors
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Texas
2025-08-04
Recruiting
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
NCT07124117Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
147
California, Texas
2025-08-04
Active, closed
Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery
NCT07027267Sinus Endoscopic Surgery, Turbinate
Spirair, Inc
Not applicable
50
Illinois, Louisiana, Texas
2025-08-04
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918Schizophrenia
DrugEmraclidine
AbbVie
Phase 2
268
Arkansas, California, Maryland, New Jersey, Texas
2025-08-04
Recruiting
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
NCT06557460Dry Age-related Macular Degeneration, Geographic Atrophy
Regenerative Patch Technologies, LLC
Phase 2
24
California, Illinois, Texas
2025-08-01
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
Severe Label Expansion for EVO Products Trial
NCT07090395Obstructive Sleep Apnea
ProSomnus Sleep Technologies
Not applicable
49
New York, Texas
2025-08-01
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2025-08
Not yet open
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
NCT07146217Bacterial Infections
Saptalis Pharmaceuticals LLC
Phase 2
30
Florida, Texas
2025-08
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
DrugsPanitumumab·Pembrolizumab
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics
Observational
75
California, Illinois, Indiana, Nevada, North Carolina, Pennsylvania, Texas, Wisconsin
2025-07-30
Recruiting
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
NCT04433572Peripheral Artery Disease, Critical Limb Ischemia
DrugTemsirolimus
Mercator MedSystems, Inc.
Phase 3
250
Louisiana, Texas
2025-07-30
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
DrugPirtobrutinib
Eli Lilly and Company
Phase 1/2
68
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Texas
2025-07-30
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Active, closed
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365Type 1 Interferonopathies
Boehringer Ingelheim
Phase 1
16
California, Pennsylvania, Texas
2025-07-29
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT07148128Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
Auricula Biosciences Inc.
Phase 1/2
110
Texas
2025-07-28
Recruiting
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
NCT06422871End Stage Renal Disease, Hemodialysis Access Failure
Merit Medical Systems, Inc.
Observational
100
District of Columbia, Florida, North Carolina, Pennsylvania, Texas, Virginia
2025-07-28
Recruiting
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
220
Colorado, Florida, Iowa, New York, Tennessee, Texas
2025-07-28
Recruiting
A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting
NCT07700966Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics, Inc
Observational
250
California, Colorado, Illinois, Texas
2025-07-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
NCT07070115Hiatal Hernia
Tela Bio Inc
Not applicable
173
Alabama, Colorado, Kentucky, North Carolina, Texas
2025-07-25
Recruiting
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225Cutaneous Melanoma, Synovial Sarcoma
DrugAnzu-cel
Immatics US, Inc.
Phase 1
15
California, Massachusetts, New York, Texas
2025-07-25
Recruiting
A Study of LY4088044 in Healthy Participants
NCT07090785Healthy
Eli Lilly and Company
Phase 1
104
California, Kansas, Texas, Utah
2025-07-24
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Recruiting
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
NCT07030712Metastatic Neoplasm
Merck Sharp & Dohme LLC
Phase 1
67
Illinois, New Jersey, Texas
2025-07-23
Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Recruiting
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
NCT07356453Advanced Solid Tumors
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06960395Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
DrugPembrolizumab
Vir Biotechnology, Inc.
Phase 1
450
Arizona, Texas
2025-07-22
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study
NCT07318051Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
Natera, Inc.
Observational
9,600
Texas
2025-07-21
Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT06779630Coronary Artery Disease
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
DrugsBNT314·Pumitamig·Bevacizumab
BioNTech SE
Phase 1/2
482
Connecticut, Michigan, Ohio, Texas
2025-07-18
Recruiting
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
NCT07023354Healthy, Hepatic Impairment
DrugVerducatib
Boehringer Ingelheim
Phase 1
32
California, Florida, Texas
2025-07-17
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
NCT06764940HER2-negative Breast Cancer Patients With Brain Metastases
DrugsUtidelone·Capecitabine
Biostar Pharma, Inc.
Phase 2
120
California, Colorado, Georgia, Illinois, Maryland, Nevada, New York, Texas
2025-07-14
Recruiting
Effects of Microprocessor-controlled Prosthetic Knees on Fall-related Health Outcomes in Limited Community Ambulators
NCT06937242Amputation, Prosthesis User, Amputation; Traumatic, Leg: Thigh, Between Hip and Knee, Limb; Absence, Congenital, Lower
Hanger Institute for Clinical Research and Education, LLC
Not applicable
100
Texas
2025-07-11
Recruiting
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
NCT07355075Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Turn Therapeutics
Phase 2/3
190
Texas
2025-07-11
Recruiting
A Study to Evaluate the SENSE Device's Ability to Detect TBI
NCT06828107Traumatic Brain Injury
Sense Diagnostics, LLC
Observational
150
Florida, Ohio, Pennsylvania, South Carolina, Texas
2025-07-11
Active, closed
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384HIV Infections
DrugsVH3810109·Fostemsavir
ViiV Healthcare
Phase 1
107
California, Florida, Illinois, Missouri, New York, Ohio, Pennsylvania, Texas
2025-07-10
Recruiting
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043Systemic Lupus Erythematosus
DrugBudoprutug
Climb Bio, Inc.
Phase 1
30
Texas
2025-07-10
Recruiting
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
NCT06799013Vaccine, Crimean-Congo Hemorrhagic Fever
HDT Bio
Phase 1
48
Texas
2025-07-10
Recruiting
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
NCT06961747Healthy Participants
DrugZilucoplan
UCB Biopharma SRL
Phase 1
15
Texas, Utah
2025-07-09
Recruiting
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
NCT06714864Catheter-Related Infections
Drug(taurolidine and heparin) catheter lock
CorMedix Therapeutics
Phase 4
36
Alabama, Arizona, California, Delaware, New Jersey, Texas
2025-07-08
Active, closed
A Prospective Study Comparing Visual Outcomes and Patient Satisfaction Following Implantation of the Clareon PanOptix Versus Tecnis Odyssey IOL in Patients Undergoing Cataract Surgery.
NCT07768475Cataracts
Nvision Laser Eye Centers
Not applicable
266
California, New York, Texas
2025-07-07
Recruiting
Radiation Free Study
NCT06549348Aortic Aneurysm
Philips Clinical & Medical Affairs Global
Not applicable
182
Alabama, Massachusetts, Pennsylvania, Texas
2025-07-03
Recruiting
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
NCT07098806Leptomeningeal Metastasis
DrugRhenium Liposome Treatment
Cerenome
Phase 1/2
24
Texas
2025-07-02
Recruiting
Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens
NCT07084545Postoperative Visual Outcomes Following Cataract Surgery in Patients With Prior Myopic Corneal Laser Vision Correction
Carl Zeiss Meditec AG
Observational
30
Texas, Virginia
2025-07
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Michigan, Texas, Vermont
2025-07
Not yet open
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
NCT06470373Neovascular Age-related Macular Degeneration (nAMD)
DrugEylea
Rophibio, Inc.
Phase 3
434
Arizona, Arkansas, Pennsylvania, Tennessee, Texas
2025-07
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725Niemann-Pick Type C Disease
DrugNizubaglustat
Azafaros B.V.
Phase 3
72
California, Minnesota, Texas, Virginia
2025-06-30
Active, closed
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1
DrugNizubaglustat
Azafaros B.V.
Phase 3
75
California, Minnesota, Texas, Virginia
2025-06-30
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
NCT06892522Multiple Myeloma
DrugsMezigdomide·Etentamig·Iberdomide·Carfilzomib
AbbVie
Phase 1/2
602
California, Colorado, Florida, Georgia, New York, North Carolina, Ohio, Texas
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
DrugNizubaglustat
Azafaros B.V.
Phase 3
147
California, Minnesota, Texas, Virginia
2025-06-30
Active, closed
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
NCT07119125Healthy Volunteers, Elevated CRP
Monte Rosa Therapeutics, Inc
Phase 1
100
Florida, Kansas, Missouri, Texas
2025-06-27
Active, closed
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers
NCT07116876Diabetic Foot Ulcer (DFU), Lower Extremity
LifeNet Health
Not applicable
120
Arizona, California, Florida, Illinois, North Carolina, Texas, Virginia
2025-06-26
Recruiting
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
NCT06982820Depressive Disorder, Major
GrayMatters Health Ltd.
Not applicable
170
Rhode Island, Texas
2025-06-25
Recruiting
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NCT07033026Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
Recruiting
Frame Support Study
NCT07083700Fertility Issues, Emotional Stress
Inception Fertility Research Institute, LLC
Not applicable
400
Texas
2025-06-23
Recruiting
Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
NCT05851430Soft Tissue Lesion
Galvanize Therapeutics, Inc.
Observational
1,000
Arizona, California, Florida, New York, North Carolina, Pennsylvania, South Carolina, Texas
2025-06-23
Recruiting
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
NCT07016750Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc.
Phase 3
16
California, Florida, Massachusetts, Ohio, Texas
2025-06-20
Active, closed
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT06912633Retinitis Pigmentosa
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
DrugPF-07328948
Pfizer
Phase 2
620
California, Florida, Illinois, Indiana, Maryland, Nebraska, Ohio, Texas
2025-06-19
Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
RxFunction Inc.
Not applicable
200
Arizona, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2025-06-17
Recruiting
Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Alpha Tau Medical LTD.
Not applicable
50
Arizona, California, Florida, Georgia, New York, Texas
2025-06-17
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
Michigan, Minnesota, New York, Texas
2025-06-16
Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629Epilepsy, Healthy Volunteer
Suninflam Inc
Phase 1
88
Arizona, Florida, Hawaii, Maryland, Michigan, New York, North Carolina, Texas
2025-06-16
By invitation
Prevention and Reduction of Falls: Testing and Evaluating Cutting Edge Haptic Technology
NCT07781397Fall Risk, Fall Risk, Fall Prevention, Accidental Falls, Accidental Falls/Prevention & Control
SuperPatch Limited LLC
Not applicable
150
Texas
2025-06-16
Recruiting
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
NCT06982352Atopic Dermatitis (AD), Psoriasis (PsO)
LAPIX Therapeutics Inc.
Phase 1
48
North Dakota, Texas
2025-06-15
Recruiting
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493Low-grade Upper Tract Urothelial Carcinoma
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals
Phase 1/2
20
Arizona, California, Florida, Minnesota, New York, Pennsylvania, Texas
2025-06-12
Recruiting
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT07075718Glaucoma
DrugsGen 2 Travoprost Intracameral Implant·Timolol eye
Glaukos Corporation
Phase 2
110
Colorado, Oklahoma, Texas
2025-06-12
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug rezetecan
GlaxoSmithKline
Phase 1/2
451
California, Colorado, New York, North Carolina, Texas, Washington, Wisconsin
2025-06-11
Recruiting
Examination of Nociscan Impact on Low Back Pain Surgical Outcomes
NCT06661850Low Back Pain
Aclarion
Observational
300
Arizona, California, Florida, Illinois, Maryland, Texas
2025-06-11
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615Non Small Cell Lung Cancer
DrugsHLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
243
Texas
2025-06-09
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
NCT07024823Chronic Kidney Disease
AstraZeneca
Phase 1
124
California, Illinois, Michigan, Minnesota, Texas
2025-06-09
Recruiting
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489Non Small Cell Lung Cancer
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Active, closed
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984Chikungunya Virus
Bavarian Nordic
Phase 3
720
California, District of Columbia, Florida, Nebraska, Ohio, Texas, Utah
2025-06-05
Recruiting
Study of AUBE00 in Patients With Solid Tumors
NCT07030959Solid Tumors
DrugCetuximab
Chugai Pharmaceutical
Phase 1
130
Michigan, Texas, Virginia
2025-06-05
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
NCT06983743Metastatic Solid Tumors
DrugsPanitumumab·Abraxane·Nab-paclitaxel·Keytruda
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
NCT06797999Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
Adcendo ApS
Phase 1/2
270
Colorado, Florida, New York, Texas
2025-06-05
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
DFT383 in Pediatric Participants With Nephropathic Cystinosis
NCT06910813Nephropathic Cystinosis
Novartis Pharmaceuticals
Phase 1/2
30
Arizona, California, Georgia, Pennsylvania, Texas
2025-06-02
Active, closed
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary
PYC Therapeutics
Phase 1/2
17
Florida, Michigan, Oregon, Texas
2025-06-01
Recruiting
Clinical Study of the inQB8 TTVR System (The MonarQ Study)
NCT06611579Tricuspid Valve Regurgitation
inQB8 Medical Technologies, LLC
Not applicable
50
California, Georgia, New York, Pennsylvania, Texas
2025-06-01
Not yet open
Single Ascending Dose and Multiple Ascending Dose Study of AVR-48
NCT06847698Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
AyuVis Research, Inc.
Phase 1
48
Texas
2025-06
Recruiting
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
NCT07046585Colo-rectal Cancer
Natera, Inc.
Observational
25,000
Texas
2025-05-30
Recruiting
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
NCT06969430Acute Myeloid Leukemia
Debiopharm International SA
Phase 1/2
154
California, Florida, Illinois, Michigan, New York, Ohio, Texas
2025-05-30
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
192
Maryland, Texas
2025-05-28
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel
Merck Sharp & Dohme LLC
Phase 2
144
Kentucky, Maryland, Texas, Virginia
2025-05-28
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
110
Florida, Kentucky, Massachusetts, Michigan, Pennsylvania, Texas
2025-05-28
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Active, closed
A Study of LY3867070 in Healthy Participants
NCT07021547Healthy
Eli Lilly and Company
Phase 1
196
California, Texas
2025-05-27
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
NCT06980428Healthy Participants, Dyslipidemia
AstraZeneca
Phase 1
136
California, Florida, Maryland, Texas
2025-05-27
Active, closed
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot
NCT06879912Hernia, Inguinal, Hernia, Ventral, Colorectal, Thoracic
Intuitive Surgical
Observational
200
California, Florida, Georgia, Illinois, Ohio, Texas
2025-05-24
Recruiting
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
NCT06983041Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Alabama, California, Michigan, New York, North Carolina, Ohio, Tennessee, Texas
2025-05-22
Recruiting
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
NCT06680752Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
DrugsFludarabine·Cyclophosphamide
ARCE Therapeutics, Inc.
Phase 1/2
49
North Carolina, Texas
2025-05-20
Recruiting
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
NCT06968741Stress Urinary Incontinence (SUI)
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Active, closed
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
InterShunt Technologies, Inc.
Not applicable
20
Arkansas, California, Indiana, Ohio, Texas
2025-05-15
By invitation
Measurement-Based Peer Supervision App for Non-Specialist Providers
NCT07082010Training of Mental Health Professionals, Training of Frontline Health Workers
Dimagi Inc.
Not applicable
55
Texas
2025-05-15
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, Florida, Georgia, Massachusetts, Minnesota, Missouri, Pennsylvania, Texas
2025-05-14
Active, closed
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519Rheumatoid Arthritis
Gilead Sciences
Phase 1
65
Alabama, California, Florida, Illinois, Louisiana, Oklahoma, Pennsylvania, Texas
2025-05-14
Active, closed
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
NCT06133387Colorectal Lesion, Colorectal Adenoma, Colorectal Polyp, Rectal Lesion
EndoQuest Robotics, Inc.
Not applicable
56
Arizona, Florida, Massachusetts, Ohio, Texas
2025-05-13
Recruiting
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
NCT06962332Hepatic Impairment, Moderate Hepatic Impairment
DrugZanzalintinib
Exelixis
Phase 1
20
Florida, Texas
2025-05-13
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
California, Illinois, Michigan, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-05-12
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
NCT06914908Chronic Rhinosinusitis With Nasal Polyps
DrugsLunsekimig·Mometasone furoate
Sanofi
Phase 2
71
California, Idaho, Oklahoma, Texas, Virginia
2025-05-12
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
California, Connecticut, Illinois, Nevada, Ohio, Texas
2025-05-07
Active, closed
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma
NCT06939283Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.
Phase 1/2
100
Arizona, Georgia, Illinois, Indiana, Texas
2025-05-07
Recruiting
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
NCT06959706Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1
50
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2025-05-07
Recruiting
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276Healthy, Hepatic Impairment
DrugMirdametinib
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 1
32
Florida, Texas
2025-05-07
Recruiting
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
NCT06779188Aging, Balance Deficits
Weinberg Medical Physics LLC
Phase EARLY_PHASE1
30
Texas
2025-05-06
Recruiting
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
NCT06975293Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
STORM Therapeutics LTD
Phase 1/2
107
California, Massachusetts, Michigan, New York, Texas, Virginia
2025-05-05
Active, closed
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773Onychomycosis of Toenail
DrugTrichostatin A
Vanda Pharmaceuticals
Phase 2
50
California, Colorado, Minnesota, Texas, Virginia
2025-05-05
Active, closed
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
NCT06800404Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
DrugAutologous HB-adMSCs
Hope Biosciences Research Foundation
Phase 2
10
Texas
2025-05-02
Recruiting
Field Shield Wound Dressing Study
NCT07337616Burn Wounds - Partial Thickness (2nd Degree)
KeriCure Medical
Not applicable
40
Arizona, Texas
2025-05-01
Recruiting
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
NCT06730347Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
MacroGenics
Phase 2
80
California, Louisiana, Michigan, Pennsylvania, Texas, Wisconsin
2025-05-01
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
DrugTebapivat
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes
Auron Therapeutics, Inc.
Phase 1
69
California, Florida, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas
2025-05-01
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618Neoplasms
Hoffmann-La Roche
Phase 1
405
California, Colorado, Connecticut, Florida, Texas
2025-04-30
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
California, Rhode Island, Texas
2025-04-29
Recruiting
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281Solid Tumors
Fortvita Biologics (USA)Inc.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Recruiting
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600Chagas Disease
DrugLXE408
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Recruiting
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761AML, Adult, MDS
DrugCytarabine
Stelexis BioSciences
Phase 1
125
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Active, closed
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
NCT07027111Chronic Inflammatory Demyelinating Polyneuropathy
DrugNVG-2089
Nuvig Therapeutics, Inc.
Phase 2
60
Texas
2025-04-25
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure
NCT06831825Heart Failure With Reduced Ejection Fraction
Medley Therapeutics
Phase 1
24
Texas
2025-04-23
Recruiting
Access Cannulation Trial II
NCT05490225Dialysis; Complications, Vascular Access Complication
Voyager Biomedical
Not applicable
100
Alabama, California, Massachusetts, New York, South Carolina, Texas, Virginia
2025-04-23
Recruiting
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038Alagille Syndrome
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
Active, closed
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 1/2
15
California, North Carolina, Pennsylvania, Texas
2025-04-22
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
California, Michigan, Ohio, Texas
2025-04-18
Active, closed
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
NCT06907511Pandemic Influenza Immunization, Healthy Volunteers
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Active, closed
A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery
NCT06664788Hemostasis, Hemostatic Techniques
Ethicon, Inc.
Not applicable
108
California, Missouri, New Jersey, New York, Texas, Utah
2025-04-16
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
DrugMRNA-1195
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447Ovarian Cancer Recurrent
DrugsMK-2010·R-DXd·Zirabev·Mvasi
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06795412Advanced Solid Tumors
DrugsPYX-201·Keytruda·Pembrolizumab
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Recruiting
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
NCT06810726Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
Estar Medical dba Medical Technologies, LTD
Phase 2
30
Texas
2025-04-15
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
Active, closed
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NCT06903065MASH
DrugAfimkibart
Hoffmann-La Roche
Phase 1
50
Arizona, Georgia, Louisiana, Nevada, Tennessee, Texas
2025-04-14
Active, closed
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
NCT06891066Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
By invitation
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT06848088Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
DrugsLutikizumab·Risankizumab
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Recruiting
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
NCT06708897CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
Lomond Therapeutics Holdings, Inc.
Phase 1
84
Kentucky, North Carolina, Ohio, Texas
2025-04-08
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
California, Florida, Missouri, Ohio, Texas
2025-04-07
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Recruiting
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
NCT06834282AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
DrugsMesna·Fludarabine·Cyclophosphamide
CERo Therapeutics Holdings, Inc.
Phase 1
18
California, Colorado, Tennessee, Texas, Washington
2025-04-07
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio, Texas
2025-04-07
Active, closed
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT06450639Duchenne Muscular Dystrophy
DrugSatralizumab
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugBitopertin
Disc Medicine, Inc
Phase 3
183
California, Florida, Massachusetts, Michigan, New York, North Carolina, Ohio, Texas
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Massachusetts, Texas, Virginia
2025-04-02
Active, closed
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432Sleep Apnea
DrugAcetazolamide
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Florida, Georgia, Texas
2025-04-02
Recruiting
Tissue Repair Gel in Venous Leg Ulcers in AU/US
NCT06707103Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugGlucoprime
TR Therapeutics
Phase 3
312
Florida, Michigan, New York, Texas
2025-04
Recruiting
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638Small Cell Lung Cancer
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
30
California, Florida, Kentucky, Ohio, Texas
2025-03-31
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
DrugsBBO-10203·MFOLFIRINOX·MFOLFOX6·Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
Context Therapeutics Inc.
Phase 1
70
Colorado, Illinois, Michigan, New Jersey, Pennsylvania, Tennessee, Texas
2025-03-31
Recruiting
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577Elevated Blood Pressure, Hypertension
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
Strategic Targeting for Optimal Prevention of Cancer
NCT03897374Early Detection of Cancer
ClinLogic LLC
Observational
120,000
Texas
2025-03-26
Recruiting
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
NCT06764771Advanced Malignant Tumors
DrugsAdagrasib·Erbitux·Opdivo·Cetuximab
Bristol-Myers Squibb
Phase 1
437
New Jersey, Pennsylvania, Tennessee, Texas
2025-03-25
Recruiting
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
NCT06880549Advanced Solid Tumors
DrugPembrolizumab
ModernaTX, Inc.
Phase 1
42
California, Michigan, Texas, Utah
2025-03-25
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
Alabama, Florida, New Jersey, Texas, Virginia
2025-03-25
Active, closed
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648Stress Urinary Incontinence (SUI)
Acoustic Wave Cell Therapy, Inc.
Not applicable
130
Arizona, Florida, Idaho, Kansas, Montana, Nevada, Ohio, Texas
2025-03-25
Recruiting
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
NCT06827613Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
DrugsSTAR0602·Sacituzumab Govitecan
Marengo Therapeutics, Inc.
Phase 1/2
50
California, Massachusetts, Ohio, Tennessee, Texas
2025-03-24
Recruiting
A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and Nerve Autograft for Peripheral Nerve Repair
NCT06529835Peripheral Nerve Injuries
Auxilium Biotechnologies
Not applicable
80
California, Maryland, New York, Ohio, Pennsylvania, Texas
2025-03-21
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Kentucky, New Mexico, Texas
2025-03-21
Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT06799065Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Active, closed
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912Lung Neoplasm Malignant
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Ribociclib·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Recruiting
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT06797635Breast Neoplasms, Breast Cancer
DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
NCT06703489Ventricular Tachycardia (VT)
Medtronic Cardiac Ablation Solutions
Not applicable
60
Massachusetts, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-03-18
Active, closed
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
California, Massachusetts, Texas
2025-03-18
Recruiting
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
NCT06641362Bradycardia, Heart Failure, Ventricular Dysfunction
VDI Technologies
Observational
360
Arizona, Illinois, Minnesota, Ohio, Texas, Virginia
2025-03-18
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Florida, Pennsylvania, South Dakota, Texas, Washington
2025-03-18
Active, closed
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008Advanced Solid Tumor
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
California, Illinois, Indiana, New York, Ohio, Texas
2025-03-13
Recruiting
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT06789445Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
BlueRock Therapeutics
Phase 1/2
54
California, Florida, Pennsylvania, Texas, Wisconsin
2025-03-10
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Active, closed
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
NCT06397131Macular Telangiectasia Type 2
Neurotech Pharmaceuticals
Phase 3
12
California, Michigan, Texas
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
California, Iowa, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas
2025-03-05
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Active, closed
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231Multiple System Atrophy
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
NCT06613217Relapsed Adult AML
Pacylex Pharmaceuticals
Phase 1
35
Texas
2025-03-03
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
DrugsPumitamig·Docetaxel
BioNTech SE
Phase 2
60
Alabama, Florida, Kentucky, New York, Texas
2025-03-03
Active, closed
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
NCT06845202Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
DrugALN-4324
Alnylam Pharmaceuticals
Phase 1/2
105
California, District of Columbia, Florida, New Jersey, North Carolina, Texas
2025-03-03
Recruiting
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06560762Heart Failure With Preserved Ejection Fraction (HFpEF)
Secretome Therapeutics
Phase 1
12
Illinois, Texas
2025-03-03
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
DrugZelenectide pevedotin
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles
NCT07222397Photodamaged Skin, Rhytids, Lines Skin, Wrinkles and Rhytides
FA Corporation
Not applicable
20
Texas
2025-03-01
Active, closed
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
NCT06812988Type 1 Diabetes Mellitus
DrugBrivekimig
Sanofi
Phase 2
84
Georgia, Michigan, Texas, Utah
2025-02-28
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Michigan, New York, Tennessee, Texas, Washington
2025-02-28
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379Solid Tumors
DrugHS-20110
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Active, closed
A Study of Oral E1018 in Healthy Adult Participants
NCT06854042Malaria, Healthy Participants
Eisai Inc.
Phase 1
32
Texas
2025-02-26
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
NCT06804824Advanced Solid Tumors
DrugsSotorasib·Trametinib
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Recruiting
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
NCT06938867E Coli Infections, Allogenic Transplant Patients
SNIPR Biome Aps.
Phase 1/2
24
California, Maryland, Minnesota, New York, Pennsylvania, Texas, Washington
2025-02-25
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
DrugsLeucovorin·Irinotecan·Adrucil·Etoposide
CStone Pharmaceuticals
Phase 1/2
800
California, Texas
2025-02-24
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Arkansas, Florida, Illinois, North Carolina, Pennsylvania, Texas
2025-02-21
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
By invitation
Clinical Trial on the Effect of the Flexible Suturing System With Anchors (FSSA) in Full-thickness Rotator Cuff Tendon Tears
NCT06868108Rotator Cuff Tears
Integrity Orthopaedics, Inc.
Observational
100
North Carolina, Texas
2025-02-20
Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT06590961Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.
Phase 1
94
Michigan, Oklahoma, Texas
2025-02-20
Recruiting
SNV4818 in Participants With Advanced Solid Tumors
NCT06736704Advanced Solid Tumors
DrugsPalbociclib·Fulvestrant
Pikavation Therapeutics, Inc.
Phase 1/2
320
California, Massachusetts, Pennsylvania, Tennessee, Texas
2025-02-20
Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400Parkinson Disease
Eli Lilly and Company
Phase 1
127
California, Florida, Michigan, Texas, Washington
2025-02-18
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
DrugsDomvanalimab·Zimberelimab·Paclitaxel·Carboplatin
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Recruiting
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase 1/2
280
California, North Carolina, Oklahoma, Texas
2025-02-17
Recruiting
OurRelationship-S: A Digital Relationship-Strengthening Program for Couples Experiencing Substance Misuse
NCT07159633Relationship Conflict, Relationship Distress
OurRelationship
Not applicable
120
Georgia, Maryland, New York, South Carolina, Texas
2025-02-15
Active, closed
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis
BioStem Technologies
Not applicable
71
Alabama, California, Florida, Illinois, Massachusetts, Missouri, New York, Texas
2025-02-14
Recruiting
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
NCT06792734Lymphoma, B-Cell
DrugBTM-3566
Bantam Pharmaceuticals
Phase 1
24
North Carolina, Texas
2025-02-14
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
DrugSevabertinib
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
MOTION Clinical Trial
NCT06843980Osteoarthritis, Knee
Moximed
Not applicable
100
California, Illinois, Nebraska, New York, Ohio, Texas
2025-02-13
Recruiting
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT06942572Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Splice Bio
Phase 1/2
57
Colorado, Florida, Massachusetts, Oregon, Texas
2025-02-11
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078Idiopathic Hypersomnia
DrugTAK-360
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Active, closed
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
NCT06255028Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
DrugAldesleukin
Century Therapeutics, Inc.
Phase 1
6
California, Illinois, Texas, Utah, Washington
2025-02-06
Active, closed
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239Systemic Sclerosis (SSc), Scleroderma
Zura Bio Inc
Phase 2
80
California, Florida, Iowa, Massachusetts, Michigan, Texas
2025-02-06
Recruiting
North American Comfilcon A Clinical Study
NCT06902584Astigmatism, Presbyopia, Ametropia
CooperVision International Limited (CVIL)
Observational
182
California, Ohio, Pennsylvania, Texas
2025-02-05
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
DrugsBGB-43395·Fulvestrant
BeOne Medicines
Phase 1
120
Iowa, Texas, Washington
2025-02-04
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
Novelty Nobility, Inc.
Phase 1
67
Michigan, Ohio, Oregon, Texas, Virginia
2025-02-03
Recruiting
Pediatric Down Syndrome Post-Approval Study
NCT06851338Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Inspire Medical Systems, Inc.
Not applicable
60
Arizona, California, Florida, New York, Ohio, Texas
2025-02
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232Recurrent Pericarditis
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Recruiting
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
NCT06805474Macular Degeneration, Geographic Atrophy, Stargardt Disease
Nanoscope Therapeutics Inc.
Observational
30
Texas
2025-01-28
Recruiting
Clinical Outcome Measure at Stryker Spine
NCT06226272Degenerative Disc Disease, Degenerative Scoliosis
VB Spine, LLC
Observational
5,222
Florida, Maine, Michigan, Ohio, Tennessee, Texas
2025-01-28
By invitation
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
NCT06701201Cancer
DrugSynKIR-310
Verismo Therapeutics
Observational
60
Colorado, Georgia, Kansas, New Jersey, Pennsylvania, Texas, Wisconsin
2025-01-27
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
California, Montana, North Carolina, Texas
2025-01-27
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
DrugFamotidine
Epkin
Phase 1
146
California, Texas
2025-01-23
Recruiting
US National TOP Registry
NCT06513091Lung Transplant
TransMedics
Observational
10,000
Arizona, California, Minnesota, North Carolina, Texas, Wisconsin
2025-01-23
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Arizona, California, Texas, Virginia, Washington
2025-01-23
Active, closed
Orthofix PhysioStim PEMF Ankle Fusion Retrospective
NCT07282067Ankle Fusion, Hindfoot Arthrodesis, Ankle Arthrodesis, Tibiotalar Arthrodesis
Orthofix Inc.
Observational
200
Arizona, California, Iowa, Maryland, North Carolina, Texas
2025-01-23
Recruiting
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
NCT06786533Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Hemogenyx Pharmaceuticals LLC
Phase 1
18
Texas
2025-01-23
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796Dermatomyositis, Polymyositis
Pfizer
Phase 3
211
Arizona, Texas, West Virginia
2025-01-22
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington
2025-01-22
Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414Higher-risk Myelodysplastic Syndrome
DrugsLisaftoclax·Azacitidine
Ascentage Pharma Group Inc.
Phase 3
490
Texas
2025-01-22
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
NCT06613360SLE, SLE (Systemic Lupus)
DrugCLN-978
Cullinan Therapeutics Inc.
Phase 1
24
Arizona, Florida, Iowa, New York, Tennessee, Texas, Utah
2025-01-21
Recruiting
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT06824064Metastatic Colorectal Cancer, Advanced Colorectal Cancer
DrugRBS2418
Riboscience, LLC.
Phase 2
150
Delaware, Texas
2025-01-17
Recruiting
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888Vestibular Schwannoma
Akouos, Inc.
Phase 1/2
27
Maryland, Minnesota, Tennessee, Texas
2025-01-17
Recruiting
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT06555419Muscular Atrophy, Spinal
DrugNusinersen
Biogen
Phase 1
78
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Pennsylvania, Texas
2025-01-16
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
NCT06667687Non-Hodgkin's Lymphoma
AbbVie
Phase 1
21
North Carolina, Oregon, Texas, Utah, Virginia
2025-01-16
By invitation
An Investigational Study Examining the Efficacy of QbMobile in Treatment Monitoring in Individuals With ADHD
NCT07217977Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Qbtech AB
Observational
175
Alabama, California, Florida, North Carolina, Texas
2025-01-15
Active, closed
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
NCT06715124Advanced Solid Tumors
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185Advanced Solid Tumor
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Recruiting
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
NCT06516653End Stage Renal Disease
Laminate Medical Technologies
Not applicable
300
California, Florida, Georgia, Massachusetts, Mississippi, Nevada, South Carolina, Texas
2025-01-13
Recruiting
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807Phenylketonurias
NGGT INC.
Phase 1/2
12
California, Minnesota, New Jersey, Pennsylvania, Texas
2025-01-10
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Fortvita Biologics (USA)Inc.
Phase 1
250
California, New Jersey, Texas, Virginia
2025-01-10
Active, closed
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
NCT06672900Healthy Volunteer
DrugsALG-000184·Carbamazepine·Itraconazole
Aligos Therapeutics
Phase 1
24
Texas
2025-01-09
Recruiting
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
NCT06809179Social Anxiety Disorder
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Recruiting
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
NCT06596291Neurogenic Detrusor Overactivity, Spinal Cord Injuries
DrugEG110A
Cyllene Therapeutics
Phase 1/2
16
California, Michigan, Ohio, Pennsylvania, Texas
2025-01-08
Recruiting
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
NCT06782555Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
DrugsEvofosfamide·Zalifrelimab·Balstilimab
ImmunoGenesis
Phase 1/2
71
Texas
2025-01-08
Active, closed
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
NCT06712251Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Venova Medical
Not applicable
20
Alabama, California, Florida, Texas
2025-01-08
Active, closed
A Study of STAR-0310 in Healthy Adult Participants
NCT06782477Healthy Participants
Astria Therapeutics, Inc.
Phase 1
40
Texas
2025-01-07
Recruiting
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
NCT06759649Neoplasm, Cancer, Malignant Tumors
DrugZimberelimab
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
By invitation
The ION Facet Screw System Ambispective Evaluation
NCT06720948Intra-facet ION 3D Facet Screw System
SurGenTec LLC
Observational
50
Indiana, Oklahoma, Texas
2025-01-01
Recruiting
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
NCT06710379Solid Tumors
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Colorado, Illinois, Ohio, Pennsylvania, Tennessee, Texas
2024-12-27
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Recruiting
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212Recurrent Head and Neck Squamous Cell Carcinoma
DrugsAdrucil·Docetaxel·Keytruda·Paclitaxel
Rakuten Medical, Inc.
Phase 3
412
California, Florida, Kentucky, Pennsylvania, Rhode Island, South Dakota, Texas
2024-12-24
Not yet open
Clinical Data Collection for Obstetric Ultrasound Algorithms
NCT06742229Pregnancy
Caption Health, Inc.
Not applicable
700
Minnesota, Texas
2024-12-20
Recruiting
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT06797336Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
240
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Alabama, Florida, Georgia, Illinois, Iowa, North Carolina, Pennsylvania, Texas
2024-12-17
Recruiting
ViewFlex X ICE First-in-Human Study
NCT06772493Cardiac Arrhythmias
Abbott Medical Devices
Observational
500
Arkansas, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Texas
2024-12-16
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
NCT06724640HIV Infections
ViiV Healthcare
Phase 1
168
Nevada, Texas
2024-12-16
Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Fresenius Kabi
Observational
40
California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington
2024-12-15
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin
AbbVie
Phase 2
185
California, Florida, Georgia, Mississippi, North Carolina, Texas
2024-12-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
NCT05460507Glioma
DrugRhenium Liposome Treatment
Cerenome
Phase 1
40
Texas
2024-12-12
Rows per page Showing 501–1000 of 1965
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,965 of those studies with a site in Texas.

How many clinical trials are recruiting in Texas?

1,184 of the 1,965 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 101 have not yet opened recruitment, 623 are active but closed to new participants, and 57 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.